Inclisiran Requests

We are currently declining to take over requests to take over prescribing and administration of Inclisiran.

Following consideration as a practice, this is because of ongoing concerns regarding the safety and resources required for practices to administer Inclisiran:

• 3 – 4 year data from trials suggests that the drug is well tolerated. However, there is currently no data from long term large outcome trials. Long-term efficacy data is expected to be published in 2026
  • Until then, long term evidence on effectiveness and safety is lacking.
  • Inclisiran is a black triangle drug.
  • This means it is a newer drug that requires extra vigilance for rare side effects.
  • Therefore clinicians administering the medication should be able to undertake shared decision making with the patient, ensuring a detailed consent is taken and documenting currently unknown long term evidence and safety profile.
  • GPs are not currently in the position to provide this information.
• General practices are not currently commissioned or resourced to provide the specialist administration/ training and monitoring that this medication requires.